Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals

• Main Authors: Andrew Hill (Author), Loai Tahat (Author), Mohammed Khalil Mohammed (Author), R.abab Fayez Tayyem (Author), Giten Khwairakpam (Author), Sanjay Nath (Author), James Freeman (Author), Ismahane Benbitour (Author), Sherine Helmy (Author)
• Format: Book
• Published: Elsevier, 2018-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuv...